TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Rating of "Buy" from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been given an average recommendation of "Buy" by the six ratings firms that are currently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued a report on the stock in the last year is $8.50.

TCRX has been the subject of several recent analyst reports. HC Wainwright reduced their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating for the company in a report on Wednesday. Morgan Stanley reaffirmed an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a research note on Friday, March 14th. Barclays reduced their price objective on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 target price on shares of TScan Therapeutics in a report on Tuesday, April 8th. Finally, Wedbush reiterated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday.

Institutional Trading of TScan Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of TScan Therapeutics by 341.1% during the 3rd quarter. Barclays PLC now owns 58,067 shares of the company's stock worth $289,000 after buying an additional 44,903 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of TScan Therapeutics by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company's stock valued at $4,849,000 after acquiring an additional 72,967 shares during the period. JPMorgan Chase & Co. boosted its position in shares of TScan Therapeutics by 94.4% in the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company's stock worth $158,000 after buying an additional 15,441 shares during the period. SG Americas Securities LLC lifted its position in TScan Therapeutics by 31.2% during the 4th quarter. SG Americas Securities LLC now owns 20,415 shares of the company's stock worth $62,000 after acquiring an additional 4,852 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new stake in shares of TScan Therapeutics during the fourth quarter valued at approximately $61,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Stock Performance

TScan Therapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $1.38. 97,796 shares of the company were exchanged, compared to its average volume of 359,600. The firm has a market cap of $77.81 million, a PE ratio of -1.30 and a beta of 1.06. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. The firm's 50-day simple moving average is $1.53 and its two-hundred day simple moving average is $2.78. TScan Therapeutics has a twelve month low of $1.02 and a twelve month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Equities analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.